Administration of neural crest-derived stem cells through intranasal administration in mouse cerebral infarction model and utilization thereof
Intranasal administration of neural crest-derived stem cells addresses the inefficiencies of conventional drug delivery by enhancing engraftment and reducing blood-brain barrier damage, offering a promising treatment for neurological diseases.
Patent Information
- Application Number
- KR1020230125028
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2023-09-19
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2043-09-19
AI Technical Summary
Existing drug delivery methods for neurological diseases, such as Alzheimer's, Parkinson's, and stroke, face challenges due to low efficiency across the blood-brain barrier, invasive procedures, and side effects from conventional administration routes like intravenous and intrathecal methods, while nasal administration has drawbacks like drug clearance and mucosal irritation.
A method involving intranasal administration of neural crest-derived stem cells to a brain-damaged animal model for screening and treatment, utilizing a kit and composition for nasal delivery to enhance engraftment and reduce blood-brain barrier damage.
Improves behavioral responses and enhances stem cell engraftment in brain tissue, reducing blood-brain barrier damage, providing a viable screening and treatment approach for brain injuries like ischemic cerebral infarction.
Smart Images

Figure 112023103885936-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to the administration of neural crest-derived stem cells via nasal administration in a mouse cerebral infarction model and the utilization thereof. Background Technology
[0002] The Central Nervous System (CNS) is a nervous system that includes the brain and spinal cord, and together with the Peripheral Nervous System (PNS), it plays a crucial role in controlling bodily mechanisms and behaviors. Diseases of the CNS include Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), stroke, and spinal cord injury. Additionally, there are numerous rare neurological diseases caused by genetic mutations that are not classified as CNS diseases, requiring the development of effective therapeutic drugs.
[0003] For the successful treatment of neurological diseases such as those mentioned above, it is crucial to efficiently deliver drugs to the nervous system. However, the delivery efficiency of therapeutic drugs is very low because the neurological tissues are surrounded by the rigid skull and the blood-brain barrier (BBB). Furthermore, conventional drug administration methods, such as intravenous or arterial administration, require administering a larger amount of drug than is needed at the affected site, which entails side effects.
[0004] Meanwhile, intrathecal or intraventricular (or intracerebroventricular) administration, known as a method for injecting drugs into the brain, allows for local administration to the affected area; however, it has limitations such as the difficulty of the procedure, high risk to the patient, and difficulty in repeated administration, which are disadvantages of invasive methods.
[0005] Nasal administration has recently garnered attention as an alternative route to injection and oral administration due to reasons such as a rapid onset of action, a relatively large absorption surface area, a non-invasive nature, and the avoidance of the first-pass effect in the liver. However, because disadvantages exist, such as drug clearance from mucosal epithelial tissue by mucus, a relatively rapid mucus turnover time, and potential irritation and toxicity with repeated administration, ongoing attempts are being made to overcome these drawbacks. Prior art literature
[0006] (Republic of Korea Published Patent) No. 10-2010-0093428 The problem to be solved
[0007] One objective of the present invention is to provide a method for screening brain damage therapeutic substances comprising the following steps:
[0008] A step of intranasally administering a candidate substance to a brain-damaged animal model excluding humans; and
[0009] A step of selecting a candidate substance as a therapeutic substance if symptoms caused by brain damage are treated after confirming the treatment pattern of the above animal model.
[0010] Another objective of the present invention is to provide a kit for screening brain injury therapeutic substances, comprising an animal model for screening brain injury therapeutic substances and instructions.
[0011] Another objective of the present invention is to provide a pharmaceutical composition for nasal administration for the prevention or treatment of brain injury comprising neural crest-derived stem cells as an active ingredient.
[0013] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art to which the present invention belongs from the description below. means of solving the problem
[0014] The present invention provides a method for screening brain damage treatment substances comprising the following steps:
[0015] A step of intranasally administering a candidate substance to a brain-damaged animal model excluding humans; and
[0016] A step of selecting a candidate substance as a therapeutic substance if symptoms caused by brain damage are treated after confirming the treatment pattern of the above animal model.
[0017] In one embodiment of the present invention, the therapeutic substance may be a stem cell, but is not limited thereto.
[0018] In one embodiment of the present invention, the stem cell may be one or more selected from the group consisting of neural crest-derived stem cells, induced pluripotent stem cells, mesenchymal stem cells, embryonic stem cells, adipose-derived stem cells, umbilical cord blood stem cells, and bone marrow stem cells, but is not limited thereto.
[0019] In one embodiment of the present invention, the neural crest-derived stem cells may be derived from inferior turbinate tissue, but are not limited thereto.
[0020] In one embodiment of the present invention, the animal may be selected from the group consisting of a mouse, a rat, a rabbit, and a pig, but is not limited thereto.
[0021] In one embodiment of the present invention, when the animal is a mouse, the stem cells are 1 x 10⁶ per animal. 2 Up to 1x10 10 Dogs may be administered, but are not limited to this.
[0022] In one embodiment of the present invention, the brain injury may be ischemic brain injury, dementia, or traumatic brain injury, but is not limited thereto.
[0023] In one embodiment of the present invention, the ischemic brain injury may include, but is not limited to, ischemic cerebral infarction.
[0024] The present invention provides a kit for screening a brain injury treatment substance, comprising an animal model for screening a brain injury treatment substance and instructions.
[0025] The present invention provides a pharmaceutical composition for nasal administration for the prevention or treatment of brain injury comprising neural crest-derived stem cells as an active ingredient.
[0026] In one embodiment of the present invention, the composition may be characterized by one or more of the following, but is not limited thereto:
[0027] Improvement of behavioral responses to brain damage;
[0028] Enhancement of stem cell engraftment in brain tissue; and
[0029] Reduced damage to the blood-brain barrier.
[0031] In addition, the present invention provides a method for treating brain damage comprising the following steps:
[0032] Step of intranasally administering the candidate substance to a brain-damaged animal model excluding humans;
[0033] A step of selecting a candidate substance as a therapeutic substance if symptoms caused by brain damage are treated after confirming the treatment pattern of the above animal model; and
[0034] A step of administering the above therapeutic substance to an individual requiring it, excluding humans.
[0035] The above therapeutic substance may be a composition comprising the neural crest-derived stem cells of the present invention as an active ingredient, but is not limited thereto.
[0036] In addition, the present invention provides an animal model for screening brain damage treatment substances for the prevention or treatment of brain damage.
[0037] In addition, a method for preventing or treating brain damage is provided, comprising the step of administering a composition containing neural crest-derived stem cells as an active ingredient to an individual in need thereof.
[0038] In addition, a composition containing neural crest-derived stem cells as an active ingredient is provided for nasal administration for the prevention or treatment of brain injury.
[0039] In addition, the present invention provides a use of a composition comprising neural crest-derived stem cells as an active ingredient for manufacturing a preparation for the prevention or treatment of brain injury for nasal administration. Effects of the invention
[0040] According to the administration of neural crest-derived stem cells via nasal administration in a mouse cerebral infarction model and its utilization, when neural crest-derived stem cells were nasally administered to an ischemic cerebral infarction model, symptoms improved in behavioral experiments, the neural crest-derived stem cells engrafted into brain tissue at an excellent level, and damage to the blood-brain barrier caused by cerebral ischemia was reduced; accordingly, this can be usefully utilized as a screening method for brain damage treatment substances. Brief explanation of the drawing
[0041] Figure 1a is a figure showing the construction and method of a cerebral ischemia mouse model. Figure 1b shows the process of preparing a mouse model of cerebral ischemia, the left photo shows the dissection and ligation of the common carotid artery, middle carotid artery, and external carotid artery, and the right photo confirms the ligation of each vessel. Figures 1c and 1d are photographs showing that the production of a cerebral ischemia mouse model was successful. Figure 2 is a photograph showing that neural crest-derived stem cells administered via the nasal administration method of the present invention have engrafted to an excellent level within brain tissue. Figure 3a is a photograph showing the results of an open field test to measure the total distance traveled for normal mice, mice with cerebral ischemia induced, and mice administered stem cells after cerebral ischemia induction, with the distance traveled shown in blue. Figure 3b is a result of quantifying the total travel distance shown in Figure 3a, and is a photograph showing that the travel distance improved as a result of administering neural crest-derived stem cells through the nasal administration method of the present invention. Figure 3c is a photograph showing the motility evaluation experiment of normal mice, mice with cerebral ischemia induced, and mice administered stem cells after cerebral ischemia induction, and Figure 3d is a graph quantifying the motility confirmed in Figure 3c. Figure 4a is a photograph showing the degree of brain-blood barrier damage in a normal mouse. Figure 4b is a photograph showing the degree of brain-blood barrier damage in mice with induced cerebral ischemia. Figure 4c is a photograph showing the results of improved brain-blood damage when neural crest-derived stem cells were administered nasally to the brain ischemia-induced mice of Figure 4b. Specific details for implementing the invention
[0042] The present invention provides a method for screening brain damage treatment substances comprising the following steps:
[0043] A step of intranasally administering a candidate substance to a brain-damaged animal model excluding humans; and
[0044] A step of selecting a candidate substance as a therapeutic substance if symptoms caused by brain damage are treated after confirming the treatment pattern of the above animal model.
[0045] In one embodiment of the present invention, the therapeutic substance may be a stem cell, but is not limited thereto.
[0046] In the present invention, a “stem cell” refers to a cell that serves as the fundamental basis of the cells or tissues constituting an organism, capable of self-renewal through repeated division, and possessing the ability to differentiate into cells with specific functions depending on the environment. They arise in all tissues during fetal development and are also found in certain tissues where cells are actively replaced, such as bone marrow and epithelial tissue, even in adulthood. Stem cells are classified according to the types of cells capable of differentiation into totipotent stem cells, which are formed when a fertilized egg begins its first division; pluripotent stem cells, which are found in the blastocyst lining formed by the continued division of these cells; and multipotent stem cells, which exist in mature tissues and organs. In this context, pluripotent stem cells are cells capable of differentiating only into cells specific to the tissues and organs in which they are contained. They are involved in the growth and development of various tissues and organs during the fetal, neonatal, and adult stages, as well as in maintaining homeostasis in adult tissues and inducing regeneration in the event of tissue damage. These tissue-specific pluripotent cells are collectively referred to as adult stem cells.
[0047] In one embodiment of the present invention, the stem cell may be one or more selected from the group consisting of neural crest-derived stem cells, induced pluripotent stem cells, mesenchymal stem cells, embryonic stem cells, adipose-derived stem cells, umbilical cord blood stem cells, and bone marrow stem cells, but is not limited thereto.
[0048] In one embodiment of the present invention, the neural crest-derived stem cells may be derived from inferior turbinate tissue, but are not limited thereto.
[0049] Human neural crest-derived inferior turbinate stem cells have the advantage of requiring minimal bleeding, pain, and time for the surgery required to obtain them, as well as the ability to continuously secure stem cells by recycling those isolated from discarded inferior turbinate tissue during inferior turbinate surgery (rhinitis surgery), which is the most frequently performed procedure in the field of otolaryngology, and the higher proliferative capacity of these stem cells compared to the aforementioned bone marrow-derived and adipose tissue-derived stem cells.
[0050] In one embodiment of the present invention, the animal may be selected from the group consisting of a mouse, a rat, a rabbit, and a pig, but is not limited thereto.
[0051] In one embodiment of the present invention, when the animal is a mouse, the stem cells are 1 x 10⁶ per animal. 2 Up to 1x10 10 Dogs may be administered, but are not limited to this.
[0052] In the present invention, “brain injury” refers to a disease expressed in a broad sense, including cognitive disorders such as dementia or mental disorders such as depression caused by damage to brain cells or brain tissue, etc., and “brain injury” may be used interchangeably with “brain injury disease,” “brain injury illness,” or “brain disease,” but is not limited thereto.
[0053] In one embodiment of the present invention, the brain injury may be ischemic brain injury, dementia, or traumatic brain injury, but is not limited thereto.
[0054] In the present invention, “traumatic brain injury” refers to damage occurring inside the skull due to external force, and may occur as a result of various accidents such as traffic accidents, industrial accidents, and sports injuries. At this time, the impairments resulting from traumatic brain injury may include, but are not limited to, impairment of consciousness, cognitive impairment, sensory impairment, and motor function.
[0055] In one embodiment of the present invention, the ischemic brain injury may include, but is not limited to, ischemic cerebral infarction.
[0056] Ischemic brain injury is typically caused by a series of complex pathological events during the onset of a stroke, which involves excitotoxicity and Zn 2+ Toxic (Zn 2+ It is triggered by toxicity-dependent, large-scale neuronal death. This acute neuronal damage leads to secondary neuronal damage in adjacent areas. Post-ischemic inflammation, apoptosis, and oxidative stress, occurring hours to days after primary ischemia, are associated with this damage. In particular, oxidative stress contributes to the late stages of ischemic damage and results in exacerbated neurological outcomes. ROS are generated during cerebral ischemia, disrupting the balance of prooxidants and antioxidants and damaging cellular macromolecules such as lipids, proteins, and nucleic acids. Furthermore, oxidative stress indirectly causes cellular damage by inducing apoptosis and inflammation. The neuroprotective effects of taurine have been reported in animal models of transient stroke, such as the middle cerebral artery occlusion (MCAO) model.
[0058] The present invention provides a kit for screening a brain injury treatment substance, comprising an animal model for screening a brain injury treatment substance and instructions.
[0059] In the present invention, the term “kit” refers to a tool including formulations, tools, kits, etc., for the treatment, alleviation, improvement, or reduction of disease progression of brain damage. In addition to the aforementioned formulations, etc., the kit of the present invention may include other components, compositions, solutions, devices, etc., which are typically required for the measurement or detection methods thereof. Specific examples may include, but are not limited to, tools, manuals, instructions, etc., required for behavioral experiments. In this case, each component may be applied one or more times without limitation on the number of times, there is no restriction on the order in which each substance is applied, and the application of each substance may proceed simultaneously or in stages.
[0060] In the present invention, the kit may include a container; instructions; and a preparation for verifying the level of treatment, etc. The container may serve to package the preparation and may also serve to store and secure it. The material of the container may take the form, for example, a bottle, a tub, a sachet, an envelope, a tube, an ampoule, etc., and these may be formed partially or wholly from plastic, glass, paper, foil, wax, etc. The container may be equipped with a cap that is initially part of the container or can be attached to the container by mechanical, adhesive, or other means and may also be equipped with a stopper that allows access to the contents by a needle. The kit may include an outer package, and the outer package may include instructions regarding the use of the components.
[0062] In the present invention, “screening” may mean selecting a substance having a specific desired property from a candidate group of various substances using a specific operation or evaluation method.
[0063] In the present invention, “candidate substance” refers to an unknown substance used in screening to treat / alleviate / improve / reduce disease progression symptoms of brain damage by administering it to an animal model of brain damage, and may be one or more selected from the group consisting of nucleotides, DNA, RNA, amino acids, aptamers, proteins, stem cells, stem cell culture media, compounds, microbial culture media or extracts, natural products, and natural extracts, but is not limited thereto.
[0064] In the present invention, “treatment” refers to any act that improves or beneficially alters the target disease and the associated metabolic abnormality symptoms, and methods such as chemotherapy, surgical procedures, or biological therapy may be used.
[0065] In the present invention, a treatment method commonly used for treating brain injury may be used, or a commonly used drug for treating brain injury may be administered, and a candidate substance disclosed in the present invention may be administered, but is not limited thereto.
[0066] In the present invention, the term “measurement” has a broad meaning that includes both detecting and confirming the presence (expression) of a target substance and detecting and confirming changes in the presence level (expression level) of the target substance. The present invention may include methods for confirming the treatment level generally used in the art, depending on the specific disease of brain injury. The measurement may be performed without limitation, including both qualitative methods (analysis) and quantitative methods. The types of qualitative and quantitative methods for measuring the treatment level of brain injury are well known in the art, and the experimental methods described in this specification are included therein.
[0067] As used herein, the term “analysis” may preferably mean “measurement,” wherein qualitative analysis may mean measuring and confirming the presence of a target substance, and quantitative analysis may mean measuring and confirming a change in the presence level (expression level) or amount of the target substance. In the present invention, analysis or measurement may be performed without limitation by including both qualitative and quantitative methods, and preferably, quantitative measurement may be performed.
[0069] The present invention provides a pharmaceutical composition for nasal administration for the prevention or treatment of brain injury comprising neural crest-derived stem cells as an active ingredient.
[0070] In one embodiment of the present invention, the composition may be characterized by one or more of the following, but is not limited thereto:
[0071] Improvement of behavioral responses to brain damage;
[0072] Enhancement of stem cell engraftment in brain tissue; and
[0073] Reduced damage to the blood-brain barrier.
[0074] In the present invention, neural crest-derived nasal inferior turbinate stem cells can be injected into a patient's body either as cells alone or in a cultured state in a culture medium.
[0075] In the present invention, the term “cellular therapeutic agent” refers to a pharmaceutical product (according to U.S. FDA regulations) used for the purposes of treatment, diagnosis, and prevention, comprising cells and tissues produced by isolation, culture, and special manipulation from humans. It refers to a pharmaceutical product in which living autologous, allogeneic, or xenogeneic cells are proliferated and selected in vitro to restore the function of cells or tissues, or in which the biological characteristics of the cells are altered by other methods, thereby using such cells for the purpose of treating, diagnosing, and preventing diseases.
[0076] The cell therapeutic agent according to the present invention may be manufactured in a unit dose form or contained in a multi-dose container by formulation using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily carried out by a person skilled in the art to which the invention belongs. The pharmaceutically acceptable carrier included in the cell therapeutic agent of the present invention is one that is commonly used in formulation and includes, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. In addition to the above components, the cell therapeutic agent of the present invention may additionally include a lubricant, a wetting agent, an emulsifier, a suspending agent, a preservative, etc.
[0077] In addition, the composition may be administered by any device capable of delivering the cell therapy agent to target cells.
[0078] The cell therapy composition of the present invention may include a therapeutically effective amount of cell therapy for the treatment of a disease. The “therapeutically effective amount” refers to an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal, or human as conceived by a researcher, veterinarian, physician, or other clinician, and includes an amount that induces the alleviation of symptoms of the disease or disorder being treated.
[0079] It is obvious to those skilled in the art that the cell therapy agent included in the composition of the present invention will vary depending on the desired effect. Therefore, the optimal cell therapy agent content can be easily determined by those skilled in the art and may be adjusted according to various factors, including the type of disease, the severity of the disease, the content of other components contained in the composition, the type of formulation, and the patient's age, weight, general health status, gender and diet, time of administration, route of administration and secretion rate of the composition, duration of treatment, and concurrently used drugs. It is important to include an amount that can obtain the maximum effect with the minimum amount without side effects, taking all of the above factors into consideration. For example, the daily dosage of the stem cells of the present invention is 1.0 × 10⁶ 4 Up to 1.0×10 11 Cells / kg body weight, preferably 1.0×10 5 Up to 1.0×10 9 Cells / kg body weight may be administered in a single dose or divided into several doses. However, it should be understood that the actual dosage of the active ingredient must be determined in light of various relevant factors such as the disease to be treated, the severity of the disease, the route of administration, the patient's body weight, age, and gender, and therefore, the above dosage does not limit the scope of the present invention in any way.
[0080] The “pharmaceutical composition” according to the present invention may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions. The excipient may be one or more selected from the group consisting of, for example, diluents, binders, disintegrants, lubricants, adsorbents, humectants, film-coating materials, and controlled-release additives.
[0081] The pharmaceutical composition according to the present invention may be formulated and used in the form of external preparations such as powders, granules, sustained-release granules, enteric granules, liquids, eye drops, ellipsoids, emulsions, suspensions, ethanol tablets, troches, fragrances, limonades, tablets, sustained-release tablets, enteric tablets, sublingual tablets, hard capsules, soft capsules, sustained-release capsules, enteric capsules, pills, tinctures, soft extracts, dry extracts, fluid extracts, injections, capsules, irrigation solutions, warning agents, lotions, pastes, sprays, inhalants, patches, sterile injectable solutions, or aerosols, according to conventional methods, and the external preparations may have formulations such as creams, gels, patches, sprays, ointments, warning agents, lotions, liniments, pastes, or cataplasms.
[0082] Carriers, excipients, and diluents that may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.
[0083] When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
[0084] Excipients such as corn starch, potato starch, wheat starch, lactose, sucrose, glucose, fructose, D-mannitol, precipitated calcium carbonate, synthetic aluminum silicate, calcium monohydrogen phosphate, calcium sulfate, sodium chloride, sodium bicarbonate, refined lanolin, microcrystalline cellulose, dextrin, sodium alginate, methylcellulose, sodium carboxymethylcellulose, kaolin, urea, colloidal silica gel, hydroxypropyl starch, hydroxypropylmethylcellulose (HPMC) 1928, HPMC 2208, HPMC 2906, HPMC 2910, propylene glycol, casein, calcium lactate, primogel, etc., as additives to tablets, powders, granules, capsules, pills, and lozenges according to the present invention; Gelatin, gum arabic, ethanol, agar powder, cellulose phthalate, carboxymethylcellulose, calcium carboxymethylcellulose, glucose, purified water, sodium casein, glycerin, stearic acid, sodium carboxymethylcellulose, sodium methylcellulose, methylcellulose, microcrystalline cellulose, dextrin, hydroxycellulose, hydroxypropyl starch, hydroxymethylcellulose, refined shellac, starch paste, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc. may be used as binders, and hydroxypropylmethylcellulose, corn starch, agar powder, methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethylcellulose, sodium alginate, Calcium carboxymethylcellulose, calcium citrate, sodium lauryl sulfate, anhydrous silica, 1-hydroxypropylcellulose, dextran, ion exchange resin, polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate, polyvinylpyrrolidone, calcium phosphate, gelled starch, gum arabic, amylopectin, pectin, sodium polyphosphate, ethylcellulose, sucrose, magnesium aluminum silicate, D-sorbitol solution, hard anhydrous silica, etc. disintegrants;Lubricants such as calcium stearate, magnesium stearate, stearic acid, hydrogenated vegetable oil, talc, lycopodium pods, kaolin, petroleum jelly, sodium stearate, cocoa paste, sodium salicylate, magnesium salicylate, polyethylene glycol 4000, PEG 6000, liquid paraffin, hydrogenated soybean oil (Lubri wax), aluminum stearate, zinc stearate, sodium lauryl sulfate, magnesium oxide, macrogol, synthetic aluminum silicate, anhydrous silica, higher fatty acids, higher alcohols, silicone oil, paraffin oil, polyethylene glycol fatty acid ether, starch, sodium chloride, sodium acetate, sodium oleate, dl-leucine, and hard anhydrous silica may be used.
[0085] As additives to the liquid formulation according to the present invention, water, dilute hydrochloric acid, dilute sulfuric acid, sodium citrate, monostearic acid sucroses, polyoxyethylene sorbitol fatty acid esters (tween esters), polyoxyethylene monoalkyl ethers, lanolin ethers, lanolin esters, acetic acid, hydrochloric acid, water ammonia, ammonium carbonate, potassium hydroxide, sodium hydroxide, prolamine, polyvinylpyrrolidone, ethylcellulose, sodium carboxymethylcellulose, etc. may be used.
[0086] In the syrup preparation according to the present invention, a solution of white sugar, other sugars or sweeteners, etc. may be used, and if necessary, flavorings, coloring agents, preservatives, stabilizers, suspending agents, emulsifiers, viscosity enhancers, etc. may be used.
[0087] Purified water may be used in the emulsion according to the present invention, and emulsifiers, preservatives, stabilizers, fragrances, etc. may be used as needed.
[0088] In the suspension agent according to the present invention, suspending agents such as acacia, tragacanthus, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, microcrystalline cellulose, sodium alginate, hydroxypropylmethylcellulose, HPMC 1828, HPMC 2906, and HPMC 2910 may be used, and surfactants, preservatives, stabilizers, coloring agents, and fragrances may be used as needed.
[0089] The injectable preparation according to the present invention comprises solvents such as distilled water for injection, 0.9% sodium chloride injection solution, Ringer's injection solution, dextrose injection solution, dextrose + sodium chloride injection solution, PEG, lactated Ringer's injection solution, ethanol, propylene glycol, non-volatile oils—sesame oil, cottonseed oil, peanut oil, soybean oil, corn oil, ethyl oleate, isopropyl myristate, and benzene benzoate; solubilizing agents such as sodium benzoate, sodium salicylate, sodium acetate, urea, urethane, monoethylacetamide, butazolidine, propylene glycol, tween, nijungtinamide, hexamine, and dimethylacetamide; and buffers such as weak acids and their salts (acetic acid and sodium acetate), weak bases and their salts (ammonia and ammonium acetate), organic compounds, proteins, albumin, peptone, and gums. It may include isotonic agents such as sodium chloride; stabilizers such as sodium bisulfite (NaHSO3), carbon dioxide gas, sodium metabisulfite (Na2S2O5), sodium sulfite (Na2SO3), nitrogen gas (N2), and ethylenediaminetetraacetic acid; sulfating agents such as sodium bisulfide 0.1%, sodium formaldehyde sulfoxylate, thiourea, disodium ethylenediaminetetraacetic acid, and sodium bisulfite acetone; non-analging agents such as benzyl alcohol, chlorobutanol, procaine hydrochloride, glucose, and calcium gluconate; and suspending agents such as sodium CMC, sodium alginate, Tween 80, and aluminum monostearate.
[0090] The suppository according to the present invention contains cocoa dough, lanolin, Witepsol, polyethylene glycol, glycerogelatin, methylcellulose, carboxymethylcellulose, a mixture of stearic acid and oleic acid, Subanal, cottonseed oil, peanut oil, palm oil, cocoa butter + cholesterol, lecithin, lanette wax, glycerol monostearate, Tween or Spandex, Imhausen, monollene (propylene glycol monostearate), glycerin, Adeps solidus, Buytyrum Tego-G, Cebes Pharma 16, hexalide base 95, Cotomar, Hydrocote SP, S-70-XXA, S-70-XX75 (S-70-XX95), Hydrocote Bases such as (Hydrokote) 25, Hydrokote 711, Idropostal, Massa estrarium (A, AS, B, C, D, E, I, T), Masa-MF, Masupol, Masupol-15, Neosupostal-N, Paramount-B, Suposiro (OSI, OSIX, A, B, C, D, H, L), suppository base type IV (AB, B, A, BC, BBG, E, BGF, C, D, 299), Supostal (N, Es), Wekovi (W, R, S, M, Fs), and Tegestor triglyceride base (TG-95, MA, 57) may be used.
[0091] Solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with the extract. In addition to simple excipients, lubricants such as magnesium styrate and talc are also used.
[0092] Liquid preparations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
[0093] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, a “pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient’s disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0094] The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects by considering all the above-mentioned factors, and this can be easily determined by a person skilled in the art to which the present invention belongs.
[0095] The pharmaceutical composition of the present invention may be administered to an individual by various routes. All modes of administration are expected, for example, oral administration, subcutaneous injection, intraperitoneal administration, intravenous injection, intramuscular injection, paraspinal (intradural) injection, sublingual administration, buccal mucosal administration, rectal insertion, vaginal insertion, ocular administration, ear administration, nasal administration, inhalation, spray through the mouth or nose, skin administration, transdermal administration, etc.
[0096] The pharmaceutical composition of the present invention is determined by the type of active ingredient drug, along with various relevant factors such as the disease to be treated, the route of administration, the patient's age, gender, weight, and the severity of the disease. Specifically, the effective dose of the composition according to the present invention may vary depending on the patient's age, gender, and weight, and generally, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight, may be administered daily or every other day, or divided into 1 to 3 doses per day. However, since the dose may be increased or decreased depending on the route of administration, the severity of the disease, gender, weight, age, etc., the above dosage does not limit the scope of the present invention in any way.
[0097] In the present invention, the term “individual” refers to a subject requiring treatment for a disease, and more specifically, to mammals such as humans or non-human primates, mice, rats, dogs, cats, horses, and cattle.
[0098] In the present invention, “administration” means providing a specific composition of the present invention to an individual by any appropriate method. In the present invention, “prevention” means any act of suppressing or delaying the onset of a target disease; “treatment” means any act of improving or beneficially altering the target disease and the associated metabolic abnormality symptoms by administering a pharmaceutical composition according to the present invention; and “improvement” means any act of reducing parameters related to the target disease, such as the severity of symptoms, by administering a composition according to the present invention.
[0100] In the present invention, when the term “comprising” is used, it means that other components may be included, rather than excluding other components, unless specifically stated otherwise. The terms “step of” or “step of” used throughout the invention do not mean “step for”.
[0102] Preferred embodiments are presented below to aid in understanding the present invention. However, the following embodiments are provided merely to facilitate a better understanding of the invention, and the scope of the invention is not limited by the following embodiments.
[0104] [Example]
[0105] Example 1. Preparation of neural crest-derived stem cells
[0106] Neural crest-derived stem cells were obtained from discarded subturbinate tissue from patients who underwent partial turbinate resection. Specifically, the tissue was washed with physiological saline and phosphate-buffered saline to 1 mm 3The tissue was cut into small pieces. They were then placed on a culture dish and covered with a sterile glass cover slide. The tissue was subsequently cultured in alpha-minimum essential medium supplemented with 1% penicillin / streptomycin and 10% fetal bovine serum at 37°C under humidified conditions containing 5% carbon dioxide. The culture medium was changed every 2 days, and the glass cover slide was removed after a total culture period of 3 weeks. Subsequently, neural crest-derived stem cells isolated from the tissue were obtained using a 0.25% trypsinin 1 mM EDTA solution.
[0108] Example 2. Preparation of a cerebral ischemia mouse model
[0109] First, a nylon thread was prepared for use in a mouse model of cerebral ischemia. Specifically, the end of a sterile Nylon 5-0 thread was brought close to a flame to make the end rounded to a size of 0.2 mm, and then cut to a total length of 10 mm.
[0110] To construct a mouse model of cerebral ischemia, male C57BL6 / J mice aged 8 weeks were provided with food and water while maintaining a 12-hour dark / light cycle, and surgery was performed after an adaptation period of at least one week. Subsequently, mice aged 9–10 weeks and weighing 20–28g were used. To induce cerebral ischemia, the mice's body temperature was maintained at 37˚C during surgery, and inhalation anesthesia was administered. The mice were laid belly-up, their limbs were immobilized, and a midline incision was made after disinfecting the neck area. Following microsurgery, the right common carotid artery, internal carotid artery, and external carotid artery were exposed. The right external carotid artery was ligated using black silk 6-0 suture, a notch was made in the right common carotid artery, and the prepared nylon 5-0 suture was inserted and inserted approximately 7–7.5 mm into the right internal carotid artery. Afterward, the right common carotid artery and internal carotid artery were ligated with black silk 6-0 sutures with the Nylon 5-0 sutures inserted to fix the Nylon 5-0 sutures in place so they would not move (Figs. 1a and 1b). The skin was then sutured, and the mouse was allowed to eat food and water even after the surgery was finished.
[0112] Dissection of the brains of some of the mice confirmed that cerebral infarction was successfully induced in the mice (Figs. 1c and 1d).
[0114] Example 3. Intranasal administration of neural crest-derived stem cells
[0115] 24 hours after inducing cerebral ischemia via surgery according to the method of Example 2, the neural crest-derived stem cells prepared in Example 1 were administered intranasally, and a total of 1 x 10 mice per experimental group were administered. 6 Dog cells were administered. PBS was administered as a control.
[0117] Experimental Example 1. Confirmation of excellent therapeutic effect on cerebral ischemia symptoms by nasal inhalation administration of neural crest-derived stem cells based on mouse behavioral experiments
[0118] Experimental Example 1-1. Increase in travel distance
[0119] One week after inducing cerebral ischemia, mouse behavioral experiments were conducted, and an open field test was performed. At this time, the experimental group and the control group were identical to those in Example 3, and it was determined whether there was a difference in total movement distance between the experimental group and the control group mice.
[0121] As a result, compared to normal mice, the total distance traveled in mice with induced cerebral ischemia was reduced due to cerebral ischemia, and it was confirmed that the total distance traveled in the experimental group in which neural crest-derived stem cells were administered intranasally to mice with induced cerebral ischemia was significantly increased (Figs. 3a and 3b).
[0123] Experimental Example 1-2. Increase in Mobility
[0124] The therapeutic effect on cerebral ischemia was confirmed by the significant increase in movement distance when neural crest-derived stem cells were administered intranasally to mice with induced cerebral ischemia according to the behavioral experiment of Experimental Example 1-1. To reconfirm this, additional motility experiments were performed on mice with induced cerebral ischemia. Specifically, the rotarod, an animal testing device, is used to evaluate motor ability by having experimental animals run on a wheel and checking the waiting time and drop time. Using this device, one control group, one mouse with induced cerebral ischemia (cerebral ischemia induction group), and one mouse with induced cerebral ischemia administered intranasally with neural crest-derived stem cells (stem cell treatment group) were each placed on drums covered on both sides (a gap of 55 mm). The number of rotations of the device per minute for each mouse was measured, and this was repeated 5 times after 3 days of training to quantify the average value (Fig. 3c).
[0126] As a result (Table 1), the control group recorded about 20 rotations per minute, while mice with induced cerebral ischemia (cerebral ischemia-induced group) recorded only about 5 rotations, showing motility that was only about 25%. On the other hand, mice administered nasally with neural crest-derived stem cells (stem cell treatment group) showed about 15 to 20 rotations and were confirmed to have recovered motility comparable to that of normal mice.
[0128] Tukey's multiple comparisons test Mean diff. 95.00% CI of diff. Adjusted P value Control group vs. cerebral ischemia-induced group 14.20 12.15 to 16.25 <0.0001 Control group vs. Stem cell treatment group 1.800 -0.2473 to 3.847 0.0831 Cerebral ischemia induction group vs. stem cell treatment group -12.40 -14.45 to -10.35 <0.0001
[0130] These results correspond to the experimental results of Experimental Example 1-1 and are statistically significant (<0.0001) just like Experimental Example 1-1, proving that the therapeutic effect can be clearly confirmed when neural crest-derived stem cells, etc. are administered nasally through the superior brain ischemia-induced mouse produced in the present invention (Fig. 3d).
[0132] Experimental Example 2. Confirmation of excellent engraftment effect of neural crest-derived stem cells in brain tissue by nasal inhalation administration
[0133] According to Example 3, after administering intranasal neural crest-derived stem cells to an ischemic brain injury mouse model, the degree of engraftment was checked using a fluorescence microscope with hNu (Human neucli) staining to confirm whether they had successfully engrafted into the brain tissue.
[0135] As a result, it was confirmed that the engraftment effect of neural crest-derived stem cells in brain tissue is excellent, which suggests that they will be effective in treating brain damage caused by cerebral ischemia (Fig. 2).
[0137] Experimental Example 3. Confirmation of the excellent effect of neural crest-derived stem cells in brain tissue by nasal inhalation administration on reducing brain-blood barrier damage
[0138] It is common for secondary brain damage to be induced due to damage to the blood-brain barrier following cerebral ischemia, while there are research findings indicating that stem cell administration induces stabilization of the blood-brain barrier. Therefore, we aimed to determine whether the degree of damage to the blood-brain barrier is reduced by administering stem cells intranasally. We analyzed whether the degree of damage to the blood-brain barrier was reduced by administering intranasal neural crest-derived stem cells to an ischemic brain injury mouse model according to Example 3. Specifically, we performed collagen fibrin protein (GFAP) staining to confirm whether the degree of damage to the blood-brain barrier was reduced in mice with induced cerebral ischemia depending on whether stem cells were administered.
[0140] As a result, it was confirmed that the expression of collagen fibrinase protein (GFAP) increased around the induced ischemia site in mice with induced ischemia compared to normal mice (green), which confirmed that damage to the blood-brain barrier occurred in the brain tissue after the induction of ischemia (Figs. 4a and 4b).
[0141] And when neural crest-derived stem cells were treated according to the nasal inhalation administration method of the present invention, it was confirmed that the expression level of GFAP in the cerebral ischemia-induced site was significantly reduced (Fig. 4c).
[0143] In summary, a mouse model of cerebral ischemia induction was successfully constructed according to the method described in the embodiments of the present invention. When neural crest-derived stem cells were administered to this cerebral ischemia-induced mouse via the intranasal administration method of the present invention, behavioral experiments confirmed an excellent increase in movement distance. Furthermore, it was confirmed that damage, such as inflammation caused by cerebral ischemia, at the blood-brain barrier was reduced to a level similar to that of normal individuals. Based on these results, the mouse model of cerebral ischemia induction according to the present invention can be usefully utilized for purposes such as screening for cerebral ischemia treatments, including via intranasal administration, as it can excellently reflect the state of cerebral ischemia in vivo.
[0145] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will understand that other specific forms can be easily modified without altering the technical spirit or essential features of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.
Claims
Claim 1 delete Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 delete Claim 10 A pharmaceutical composition for nasal administration for the prevention or treatment of brain injury, comprising as an active ingredient neural crest-derived stem cells isolated from inferior turbinate tissue, wherein the brain injury is one or more ischemic brain injuries including ischemic stroke or cerebral infarction, and the composition is administered to an individual in whom damage to the blood-brain barrier has occurred. Claim 11 In claim 10, the above composition is a pharmaceutical composition characterized by one or more of the following: improvement of behavioral responses to brain injury; increased engraftment of stem cells in brain tissue; and reduction of brain-blood barrier damage. Claim 12 In claim 10, the above composition is a pharmaceutical composition administered to an individual in whom secondary brain damage caused by damage to the blood-brain barrier has been induced. Claim 13 A pharmaceutical composition according to claim 10, characterized in that the individual has increased expression of glial fibrillary acidic protein (GFAP).
